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Abstract
Background: Cardiac troponin is the biochemical gold standard to diagnose acute myocardial infarction. Interestingly
however, elevated cardiac troponin concentrations are also frequently observed during and after endurance-type exercise.
Oxidative stress associated with prolonged exercise has been proposed to contribute to cardiac troponin release. Therefore,
the aim of this study was to assess the effect of 4 week astaxanthin supplementation (a potent cartenoid antioxidant) on
antioxidant capacity and exercise-induced cardiac troponin release in cyclists.
Methods: Thirty-two well-trained male cyclists (age 2565, weight 7367 kg, maximum O2 uptake 6065 mL?kg
21?min21,
Wmax 5.460.5 W?kg
21; mean 6 SD) were repeatedly subjected to a laboratory based standardized exercise protocol before
and after 4 weeks of astaxanthin (20 mg/day), or placebo supplementation in a double-blind randomized manner. Blood
samples were obtained at baseline, at 60 min of cycling and immediately post-exercise (< 120 min).
Results: The pre-supplementation cycling trial induced a significant rise of median cardiac troponin T concentrations from
3.2 (IQR 3.0–4.2) to 4.7 ng/L (IQR 3.7–6.7), immediately post-exercise (p,0.001). Four weeks of astaxanthin supplementation
significantly increased mean basal plasma astaxanthin concentrations from non-detectable values to 175686 mg?kg21.
However, daily astaxanthin supplementation had no effect on exercise-induced cardiac troponin T release (p = 0.24), as
measured by the incremental area under the curve. Furthermore, the elevation in basal plasma astaxanthin concentrations
was not reflected in changes in antioxidant capacity markers (trolox equivalent antioxidant capacity, uric acid, and
malondialdehyde). Markers of inflammation (high-sensitivity C-reactive protein) and exercise-induced skeletal muscle
damage (creatine kinase) were equally unaffected by astaxanthin supplementation.
Conclusion: Despite substantial increases in plasma astaxanthin concentrations, astaxanthin supplementation did not
improve antioxidant capacity in well-trained cyclists. Accordingly, exercise-induced cardiac troponin T concentrations were
not affected by astaxanthin supplementation.
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Introduction
Myocardial necrosis is accompanied by the release of cardiac
troponin (cTn) into the bloodstream, which makes cTn the
preferred biomarker for the diagnosis of acute myocardial
infarction (AMI) [1]. Interestingly, elevated cTn concentrations
are not restricted to AMI, but are also observed in a wide range of
cardiac and non-cardiac pathologies e.g. renal failure, pulmonary
embolism, myocarditis and congestive heart failure (an extensive
list has been published in [2,3]). In all these pathological settings
elevated cTn concentrations are consistently associated with poor
prognosis [4–7]. An intriguing example of non-AMI related cTn
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release in healthy subjects occurs after moderate and highly
intensive endurance exercise such as marathons, cycling events
and long-distance walking [8–12]. cTn levels in blood rise quickly
during exercise, and unlike AMI, they return quickly to normal in
approximately 24–48 hours [9,13,14]. To date it has not been
clarified whether exercise-induced cTn release is a physiologic or
pathologic phenomenon. There is no epidemiological evidence
thus far that links the magnitude of exercise-induced cTn release
to poor prognosis. The faster kinetics of exercise-induced cTn
release, and the possible presence of a cytosolic unbound cTn
fraction in the cardiomyocyte [15], triggered the postulation of a
distinct release model for cTn during exercise, unrelated to
myocardial cell death [16]. This hypothetical model states that
exercise-induced cTn release could be attributed to increased
cardiomyocyte permeability (through mechanical stress or in-
creased production of oxidative radicals) and subsequent early
troponin release from a cytosolic cTn pool, possibly through
membrane blebbing [16,17]. This atypical model of benign cTn
release was coined the ‘‘reversible injury hypothesis’’. It challenges
the dogma that increased cTn concentrations always reflect cell
death, and unites two apparently incompatible observations: 1) the
frequent occurrence of exercise-induced cTn release [18], and 2)
the limited cardiomyocyte regenerative capacity [19]. This
hypothesis however, has been opposed by a number of observa-
tions that warrant prudence before classifying all exercise-induced
cTn rises as benign. First, the most pronounced post-exercise cTn
concentrations have been observed in the least trained subjects
[20]. Second, baseline cTn levels, which are robust predictors of
cardiovascular morbidity and mortality in virtually every patient
group investigated, explained up to 80% of the cTn variation after
exercise [21]. Finally, a strong correlation has been observed
between post-exercise cTn concentrations and short-term right
ventricular functional impairment [22]. Over time, repetitive
strain on the right ventricle may lead to chronic structural
changes, as demonstrated by a high prevalence of chronic
structural changes in athletes with the highest cumulative exposure
to endurance competition [23–25].
The identification of the biological mechanism that underlies
exercise-induced cTn release is an active and relevant topic of
discussion [17]. Oxidative stress associated with prolonged
exercise has been proposed to contribute to cTn release [26,27].
If true, supporting endogenous defense systems with additional
doses of antioxidants could therefore be an important strategy to
examine the role of oxidative stress as a mechanism for exercise-
induced cTn release. Therefore, we subjected male trained cyclists
to a laboratory based standardized exercise protocol before and
after 4 weeks of astaxanthin (a potent cartenoid antioxidant) or
placebo supplementation. We hypothesized that astaxanthin
supplementation attenuates oxidative stress, inflammation and
muscle damage following cycling exercise and hence reduces
exercise-induced cardiac troponin release.
Materials and Methods
Ethics Statement
This study complies with the Declaration of Helsinki and was
approved by the Institutional Review Board and Ethics Commit-
tee at Maastricht University Medical Center. All participants gave
written informed consent. This study was registered at clinical-
trials.gov as NCT01241877. The protocol for this trial and
supporting CONSORT checklist are available as supporting
information; see Checklist S1 and Protocol S1.
Trial Design
The study was designed as a double-blind, placebo-controlled
randomized parallel group trial. Thirty-two healthy male volun-
teers were recruited from 01-12-2010 till 01-06-2011 via local
cycling clubs. We included healthy, young (age between 18 and 30
years), endurance-trained male cyclists, with a training history of
more than 3 sessions per week for more than one year. The study
was conducted between 01-01-2011 and 01-11-2011 at the
Department of Human Movement Sciences at Maastricht
University Medical Center. All subjects were competitive cyclists
or triathletes who had been involved in regular cycling training
(more than 3 sessions per week with 1165 hours per week) for at
least two years.
Study Protocol
The study was designed to examine the effect of 4 weeks of
astaxanthin supplementation on exercise-induced cTn release.
This study is part of a greater randomized trial examining the
impact of astaxanthin supplementation on muscle metabolism and
exercise performance, as primary outcome measures [28]. Briefly,
subjects visited our laboratory on four occasions, two of which
were scheduled prior to the start of the main experimental period.
The first visit consisted of an incremental cycling exercise test to
exhaustion to determine subjects’ maximal workload capacity
(Wmax) and maximum oxygen uptake (VO2 max). The second visit
consisted of a familiarization test that was identical in design as the
main experimental test days. The actual experimental period (visit
3 and 4) consisted of two identical standardized cycling trials,
separated by a 4 week supplementation period with astaxanthin or
placebo. The pre- and post-supplementation trials were performed
on the same time and day of the week for each subject. On each
test day, subjects reported to the laboratory at 08.00 after an
overnight fast. A Teflon catheter (Baxter, Utrecht, the Nether-
Figure 1. Flow chart of the trial.
doi:10.1371/journal.pone.0079280.g001
Antioxidant Supplementation and Cardiac Troponin
PLOS ONE | www.plosone.org 2 November 2013 | Volume 8 | Issue 11 | e79280
lands) was inserted into an antecubital vein for blood sampling.
The exercise protocol consisted of 60 min steady-state moderate
intensity exercise (50% Wmax) followed by a validated time-trial
[29], in which athletes performed a set amount of work at maximal
performance for about < 60 min. Blood samples were obtained at
baseline, at 60 min of cycling and immediately post-exercise (<
120 min).
Supplementation Protocol
Participants were randomly assigned in a double-blind fashion
to receive either 20 mg/day of astaxanthin or placebo for 4 weeks.
Randomization was performed by a random number generator
(www.random.org). Astaxanthin is a xanthophyll carotenoid
pigment with potent antioxidative and anti-inflammatory capac-
ities and has previously been shown to attenuate exercise-induced
oxidative damage in mouse skeletal and cardiac muscle [30,31].
The astaxanthin supplementation consisted of a natural astax-
anthin extract from the microalga Haematococcus pluvialis (80 mg of
5% astaxanthin) dissolved in sun flower oil in gelatin capsules with
added vitamin C (60 mg per capsule) and vitamin E (10 mg per
capsule) (BioReal, Gustavsberg, Sweden). Participants ingested 2
capsules (4 mg astaxanthin/capsule) with breakfast and 3 capsules
with dinner throughout the 4-week intervention period. The
placebo supplement was externally identical to the astaxanthin
capsule, without the phytonutrient content. The placebo group
followed the same supplementation protocol as the astaxanthin
group. The supplementation was assigned by an independent
investigator, so that both the subjects and investigators were
blinded to the treatment. Supplementation compliance was
assessed by the number of pills that were left over in the pill
bottle after the supplementation period.
Physical Activity and Dietary Standardization
During the study, subjects were allowed to consume their
normal diets but were instructed to refrain from astaxanthin-rich
foods such as salmon, lobster, and shrimp. All subjects were also
instructed to refrain from physical exercise for two days before
each test day. In addition, we asked subjects to record their food
intake for two days before the pre-supplementation test day and to
replicate their food intake two days before the post-supplementa-
tion test day. All subjects received a standardized dinner the
evening prior to each experimental test day (6264 kJ?kg body-
weight21, consisting of 50 energy percent (En%) carbohydrate,
10 En% protein, and 40 En% fat).
Biochemical Analyses
Plasma and serum samples were stored at 280uC until analysis.
Serum cardiac troponin T (cTnT) was measured using the high-
sensitivity cTnT assay (Roche Diagnostics) on the Elecsys 2010
using lot no. 167650. The measuring range of this assay is 3–
10,000 ng/L, with a 99th percentile in apparently healthy
individuals at 14 ng/L, which is clinically employed to diagnose
AMI [32]. Serum creatine kinase (CK) was measured on Roche
Cobas 6000 analyzer. Serum high-sensitivity C-reactive protein
(hsCRP) was measured on the BN Prospec (Siemens). Plasma
carotenoid concentrations and antioxidant markers (trolox equiv-
alent antioxidant capacity (TEAC), uric acid, and malondialde-
hyde (MDA)) have been measured in the setting of a previous
study and reported accordingly [28].
Statistical Analysis
To be able to detect a 10% reduction in exercise-induced cTn
release (from 7.061.4 to 6.361.3 ng/L) due to astaxanthin, with a
two-sided significance level of 5% and 80% power, a total of 32
subjects were recruited. No intervention has been reported that
effective reduces exercise-induced cTn release. The effect size of
10% was therefore derived from the antioxidant-induced reduc-
tion of skeletal muscle damage after exercise [33,34]. In these
studies 20–30% reductions of CK levels were obtained through
antioxidant supplementation. Assuming a similar mechanism and
effect size in cardiac muscle, we felt that a ,10% reduction would
exclude a major role for antioxidants in this setting. The
Kolmogorov-Smirnov test was used to evaluate the normality of
the data. Participant characteristics are presented as the mean 6
SD, biochemical parameters are shown as median and inter-
quartile range. Paired data was tested using the Mann Whitney U
test, non-paired data via the Wilcoxon Signed-Rank test. The
incremental area under the curve (iAUC) was used as a summary
measure for exercise-induced cTnT release. The effect of
antioxidant supplementation was assessed by analysis of variance
(ANOVA), using the iAUC at pre-supplementation as covariate.
Statistical analysis was performed using SPSS, version 18.0.
Results
Participants Characteristics
A detailed flow of the trial is described in Figure 1. Thirty-two
well-trained cyclists were included in the study. One subject in the
placebo group left the study prematurely for medical reasons,
unrelated to the study protocol. Subjects’ baseline characteristics
are shown in Table 1. No differences in age, weight, maximum O2
uptake, maximum workload capacity or the average hours of
training per week were observed between the placebo (n= 15) and
astaxanthin group (n= 16).
Table 1. Participants characteristics.
All participants Placebo Antioxidant
n=31 n=15 n=16
Age (years) 24.764.7 25.065.5 24.563.9
Weight (kg) 72.967.2 73.068.5 72.966.1
Maximum O2 uptake (mL?kg
21?min21) 60.264.8 59.565.4 60.964.3
Maximum workload (W?kg21) 5.460.5 5.360.5 5.560.5
Training (hours/week) 10.964.2 10.564.9 11.263.5
Data are presented as mean 6 SD.
doi:10.1371/journal.pone.0079280.t001
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Astaxanthin Supplementation
In the placebo group, plasma astaxanthin concentrations were
undetectable throughout the study. In the astaxanthin group,
plasma astaxanthin concentrations were significantly increased
from non-detectable values to 175686 mg?kg21. There were no
differences in other cartenoid intake within or between groups
during the study.
Figure 2. cTnT, CK and hsCRP concentrations during the pre- and post-supplementation exercise trials. A, D, G. Whole group cTnT, CK
and hsCRP concentrations during the pre-supplementation exercise trials. B, E, H. cTnT, CK and hsCRP concentrations in the placebo group measured
during the pre- and post-supplementation cycling trials. C, F, I. cTnT, CK and hsCRP concentrations in the astaxanthin group during the pre- and post-
supplementation trials. ***denotes a significant increase from baseline (P,0.001). Values are median and interquartile range.
doi:10.1371/journal.pone.0079280.g002
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Astaxanthin does not Reduce the Magnitude of Exercise-
induced Cardiac Troponin Release
The pre-supplementation cycling trial induced a significant
increase in cTnT, from overall median cTnT 3.2 (IQR 3.0–4.2) to
4.7 ng/L (IQR 3.7–6.7) immediately post-exercise (p,0.001)
(Figure 2A). Four weeks of astaxanthin supplementation did not
affect baseline cTnT concentrations compared to placebo
supplementation (median 3.0 (IQR 3.0–4.5) versus 3.7 ng/L
(IQR 3.0–4.6)) (p = 0.63). The post-supplementation cycling trial
resulted in a significant increase from median cTnT 3.0 (IQR 3.0–
4.5) to 5.7 ng/L (IQR 3.0–6.9) in the placebo group (Figure 2B),
and from median cTnT 3.7 (IQR 3.0–4.7) to 4.8 ng/L (IQR 3.6–
6.9) in the astaxanthin group, immediately post-exercise
(Figure 2C) (both p,0.01). Despite the increase in basal
astaxanthin concentrations, there were no differences between
groups in the post-supplementation incremental area under the
cTnT curve (p= 0.24). Furthermore, there was no significant
association between the supplementation-induced astaxanthin
concentration and exercise-induced cTn release (data not shown).
Astaxanthin does not Improve Antioxidant Capacity in
Highly Trained Individuals
Antioxidant capacity markers including trolox equivalent
antioxidant capacity (TEAC), uric acid, and malondialdehyde
(MDA) did not differ between the pre- and post-supplementation
exercise trials or between groups. Markers of exercise-induced
skeletal muscle damage (CK) (Figure 2, D–F) and inflammation
(hsCRP) (Figure 2, G–I) were equally unaffected by astaxanthin
supplementation. Furthermore, no evident relationship was
detected between any of the antioxidant capacity markers and
post-exercise cTnT concentrations (Figure S1).
Discussion
In the present study we demonstrate that 4 weeks antioxidant
supplementation did not improve antioxidant capacity, and did
not reduce exercise-induced cTn release in well-trained individ-
uals.
Intensive physical activity is characterized by an increase in
oxygen consumption with concomitant production of reactive
oxygen species. In the setting of AMI, generation of reactive
oxygen species during the reintroduction of blood flow to a
previously ischemic area, is a well established contributor to
myocardial reperfusion injury and cTn release [35]. We hypoth-
esized that a similar mechanism would apply in the setting of
exercise-induced cTn release, and that oxidative stress associated
with endurance exercise causes reversible or irreversible damage to
cardiomyocytes with consequent release of cTnT.
The lack of any improvement in antioxidant capacity in the
present study was unlikely due to non-compliance of the subjects.
Compliance, estimated by pill-counting was .90% in 28 out of 31
subjects. Adequate compliance was also evident from strongly
increased plasma astaxanthin concentrations. Furthermore, the
effect of astaxanthin supplementation was not masked by
differences in the total carotenoid intake during the experimental
period or between groups. In previous studies, prolonged
astaxanthin supplementation (12 weeks, 8 mg/day [36] or 12
weeks, 20 mg/day [37] improved total antioxidant capacity,
attenuated MDA and lipid peroxidation. Possibly the highly
trained state of our participants, which is associated with already
substantially elevated endogenous antioxidant capacity [38,39],
precluded an additional improvement through antioxidant sup-
plementation.
In line with the absence of any effect of astaxanthin on
antioxidant capacity, no significant reduction of exercise-induced
cTn release were observed in subjects following 4 weeks of
antioxidant supplementation. To date, one previous study
addressed the hypothesis that antioxidant supplementation (tart
cherry juice) reduces exercise-induced cTn release in humans, and
concluded that 5 days of antioxidant supplementation did not
attenuate circulating cTn following a marathon run [13,40]. Our
study complements this work and deals with some limitations of
the original report related to power, duration of antioxidant
supplementation, and study design: we extended the period of
antioxidant supplementation, increased the number of study
subjects and applied a pre-post test design that allows each subject
to act as its own control. Our approach circumvents power
problems that may arise from the high between-person variation in
exercise-induced cTn release [21], and exploits the good
reproducibility and low within-person variation of cTn release
during two identical exercise bouts [21].
In conclusion, despite substantial increases in plasma astax-
anthin concentrations, astaxanthin supplementation did not
improve antioxidant capacity in highly trained cyclists. Accord-
ingly, exercise-induced cTnT concentrations were not affected by
astaxanthin supplementation.
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